1. Home
  2. YDKG vs APVO Comparison

YDKG vs APVO Comparison

Compare YDKG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDKG

Yueda Digital Holding Class A Ordinary Share

HOLD

Current Price

$1.08

Market Cap

5.3M

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$3.95

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDKG
APVO
Founded
2005
2016
Country
China
United States
Employees
18
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.1M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
YDKG
APVO
Price
$1.08
$3.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
24.9K
31.0K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.50
52 Week High
$3.90
$10.70

Technical Indicators

Market Signals
Indicator
YDKG
APVO
Relative Strength Index (RSI) 63.13 39.18
Support Level $0.81 $3.81
Resistance Level $1.13 $4.84
Average True Range (ATR) 0.07 0.25
MACD 0.01 -0.03
Stochastic Oscillator 90.48 10.00

Price Performance

Historical Comparison
YDKG
APVO

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a Web3 and digital company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: